Tucson, AZ, September 09, 2021 --(PR.com)-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of breast cancer affecting about 50,000 patients each year in the US.
Search
Recent Posts
See AllTucson, AZ, October 12, 2021 --(PR.com)-- NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Inst
Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO
Tucson, AZ, July 23, 2021 --(PR.com)-- NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics wi